Bristol Myers Squibb (BMY) EBT Margin Growth (1y) (2010 - 2026)
Bristol Myers Squibb (BMY) EBT Margin Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EBT Margin Growth (1y) (Qtr) |
| 1 |
Gsk |
96,436,181.12 Bn |
96,436,176.16 Bn |
7.76 Bn |
6.00 |
| 2 |
Eli Lilly |
1,017.30 Bn |
1,012.01 Bn |
16.22 Bn |
1,755.00 |
| 3 |
Johnson & Johnson |
579.61 Bn |
557.55 Bn |
15.96 Bn |
-3,737.00 |
| 4 |
AbbVie |
402.30 Bn |
392.96 Bn |
10.78 Bn |
-552.00 |
| 5 |
Merck |
294.24 Bn |
288.59 Bn |
12.09 Bn |
-5,950.00 |
| 6 |
Amgen |
191.82 Bn |
179.78 Bn |
5.87 Bn |
-3.00 |
| 7 |
Gilead Sciences |
155.93 Bn |
148.21 Bn |
5.52 Bn |
1,234.00 |
| 8 |
Pfizer |
149.05 Bn |
136.28 Bn |
-1.21 Bn |
372.00 |
| 9 |
Bristol Myers Squibb |
116.33 Bn |
105.88 Bn |
8.07 Bn |
168.00 |
| 10 |
Novartis Ag |
112.59 Bn |
111.90 Bn |
- |
- |
| Date | Value |
|---|
| Mar 31, 2026 |
168.00 |
| Dec 31, 2025 |
1,034.00 |
| Sep 30, 2025 |
1,139.00 |
| Jun 30, 2025 |
391.00 |
| Mar 31, 2025 |
12,358.00 |
| Dec 31, 2024 |
-1,317.00 |
| Sep 30, 2024 |
-539.00 |
| Jun 30, 2024 |
-602.00 |
| Mar 31, 2024 |
-12,149.00 |
| Dec 31, 2023 |
-171.00 |
| Sep 30, 2023 |
-20.00 |
| Jun 30, 2023 |
9.00 |
| Mar 31, 2023 |
995.00 |
| Dec 31, 2022 |
80.00 |
| Sep 30, 2022 |
114.00 |
| Jun 30, 2022 |
320.00 |
| Mar 31, 2022 |
-837.00 |
| Dec 31, 2021 |
10,993.00 |
| Sep 30, 2021 |
-286.00 |
| Jun 30, 2021 |
-279.00 |
